You are now leaving www.kedrion.at. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

The Kedrion portfolio of plasma-derived therapies treats a range of disorders and conditions from Albumin for critical care to Anti-D i.m. Immunoglobulin (RhoGAM®) to prevent hemolytic disease in the newborn.  

Our continuing commitment to research, development and innovation, along with our growing industrial capacity and expanding international market presence, contributes to an ever-greater access to effective healthcare for people suffering these debilitating conditions.

Our Therapeutic Areas include: